➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Dow
McKesson
Express Scripts
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,296,815

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,296,815
Title:Antibodies with enhanced or suppressed effector function
Abstract: Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components.
Inventor(s): D\'Angelo; Igor (Port Moody, CA), Bleile; Dustin (Vancouver, CA), Tom-Yew; Stacey A. L. (New Westminster, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula I. (Vancouver, CA), Ohrn; Anders (Vancouver, CA), Poon; David K. Y. (Richmond, CA), Dixit; Surjit B. (Richmond, CA)
Assignee: Zymeworks Inc. (Vancouver, British Columbia, CA)
Application Number:13/638,362
Patent Claims:see list of patent claims

Details for Patent 9,296,815

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Zymeworks Inc. (Vancouver, British Columbia, CA) 2030-03-29 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Zymeworks Inc. (Vancouver, British Columbia, CA) 2030-03-29 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Start Trial Zymeworks Inc. (Vancouver, British Columbia, CA) 2030-03-29 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12   Start Trial Zymeworks Inc. (Vancouver, British Columbia, CA) 2030-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Baxter
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.